DROTAVERINE HCL 80 MG + MEFENAMIC ACID 250 MG TAB
₹780.00
OXDROT – M by Floriwa Labs is a powerful antispasmodic and analgesic combination formulated to provide effective relief from abdominal pain and menstrual cramps. It contains Drotaverine Hydrochloride 80 mg and Mefenamic Acid 250 mg, offering dual action against spasms and pain.
Drotaverine is an antispasmodic agent that relaxes smooth muscles of the gastrointestinal and genitourinary tract, helping reduce spasmodic pain. Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) that relieves pain and inflammation.
OXDROT – M is widely prescribed for dysmenorrhea (painful periods), abdominal colic, and spasmodic pain conditions. Manufactured under stringent pharmaceutical standards, it ensures safety, quality, and effective pain management.
Drotaverine Hydrochloride 80 mg
Mefenamic Acid 250 mg
Dosage Form: Tablet
OXDROT – M is indicated for:
Primary and secondary dysmenorrhea
Menstrual cramps
Abdominal pain
Gastrointestinal spasms
Uterine spasms
Colicky pain
Dual action formula: antispasmodic + pain relief
Relieves menstrual cramps effectively
Reduces abdominal spasms
Quick and effective pain control
Trusted quality from Floriwa Labs
Drotaverine relaxes smooth muscle by inhibiting phosphodiesterase IV, reducing muscle spasms. Mefenamic Acid inhibits prostaglandin synthesis, decreasing pain and inflammation.
Take OXDROT – M strictly as prescribed by a registered medical practitioner. Swallow with water. Dosage depends on severity and medical condition.
Use under medical supervision
Avoid in patients with severe liver or kidney disorders
Not recommended in late pregnancy unless prescribed
Do not exceed recommended dosage
Store in a cool and dry place
Effective gynecology pain management product
High-quality manufacturing standards
Reliable combination therapy
Suitable for PCD Pharma Franchise opportunities
| Packaging | BLISTER, 10*10 |
|---|
“Floriwa Labs stands among the best Gynae PCD pharma companies in India with a strong focus on quality, care, and partnerships.”
